natgillin/translations-raw huggingface dataset:
PegIntron 80 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b 
PegIntron 80 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku peginterferon alfa-2b
PegIntron 50 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b 
PegIntron 50 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku peginterferon alfa-2b
PegIntron 150 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b 
PegIntron 150 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku peginterferon alfa-2b
Common side effects (may affect up to 1 in 10 people): - fungal infection, common cold, cold sores, pharyngitis (sore throat), sinusitis, ear infection, coughing, throat pain, feeling cold, eye pain, - decrease in blood clotting cells called platelets, that may result in easy bruising and spontaneous bleeding, swollen glands (swollen lymph nodes), blood thyroid tests abnormalities, decrease in thyroid gland activity, which may make you feel tired, depressed, increase your sensitivity to cold and other symptoms, - wanting or attempting to harm yourself aggressive behaviour, agitation, anger, mood changes, nervousness or restlessness, depression, feeling anxious, trouble falling asleep or staying asleep, emotional instability, poor quality sleep, feeling sleepy, disturbance in attention. 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): - glivične okužbe, navaden prehlad, herpesni izpuščaji, faringitis (vnetje grla), sinusitis, okužba ušes, kašelj, bolečine v grlu, občutek mrazenja, očesne bolečine, - zmanjšanje števila celic za strjevanje krvi, ki jim pravimo trombociti, kar lahko vodi do nagnjenosti k nastanku podplutb in spontanih krvavitev, otekle žleze (otekle bezgavke), nenormalni izvidi krvnih preiskav delovanja žleze ščitnice, zmanjšanje delovanja žleze ščitnice, ki lahko povzroči utrujenost, depresijo, povečanje občutljivosti na mraz in druge simptome,
PegIntron 150 micrograms powder and solvent for injection peginterferon alfa-2b 
PegIntron 150 mikrogramov prašek in vehikel za raztopino za injiciranje peginterferon alfa-2b
PegIntron 100 micrograms powder and solvent for injection peginterferon alfa-2b 
PegIntron 100 mikrogramov prašek in vehikel za raztopino za injiciranje peginterferon alfa-2b
PegIntron 50 micrograms powder and solvent for injection peginterferon alfa-2b 
PegIntron 50 mikrogramov prašek in vehikel za raztopino za injiciranje peginterferon alfa-2b
Please refer to the ribavirin SmPC for capsules or oral solution when PegIntron is to be used in combination with ribavirin. 
Če bo bolnik zdravilo PegIntron uporabljal sočasno z ribavirinom, prosimo, glejte SmPC za ribavirin trde kapsule ali peroralno raztopino.
PegIntron 80 micrograms powder and solvent for injection peginterferon alfa-2b 
PegIntron 80 mikrogramov prašek in vehikel za raztopino za injiciranje peginterferon alfa-2b
PegIntron 100 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b 
PegIntron 100 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku peginterferon alfa-2b
PegIntron 120 micrograms powder and solvent for injection peginterferon alfa-2b 
PegIntron 120 mikrogramov prašek in vehikel za raztopino za injiciranje peginterferon alfa-2b
EU/1/00/131/015 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/028 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs) 
EU/1/00/131/028 (12 vial praška, 12 ampul vehikla, 12 injekcijskih brizg, 24 injekcijskih igel, 12 čistilnih tamponov)
EU/1/00/131/025 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/030 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs) 
EU/1/00/131/030 (12 vial praška, 12 ampul vehikla, 12 injekcijskih brizg, 24 injekcijskih igel, 12 čistilnih tamponov)
EU/1/00/131/010 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/027 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs) 
EU/1/00/131/027 (12 vial praška, 12 ampul vehikla, 12 injekcijskih brizg, 24 injekcijskih igel, 12 čistilnih tamponov)
EU/1/00/131/023 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/024 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs) 
EU/1/00/131/024 (4 viale praška, 4 ampule vehikla, 4 injekcijske brizge, 8 injekcijskih igel, 4 čistilni tamponi)
EU/1/00/131/020 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/029 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs) 
EU/1/00/131/029 (12 vial praška, 12 ampul vehikla, 12 injekcijskih brizg, 24 injekcijskih igel, 12 čistilnih tamponov)
Dose reduction of PegIntron in children and adolescents is accomplished by modifying the recommended dose in a two-step process from the original starting dose of 60 g/m 2/week, to 40 g/m 2/week, then to 20 g/m 2/week, if needed. 
Pri otrocih in mladostnikih je prvo zmanjšanje odmerka zdravila PegIntron na 40 µg/m2/teden in drugo zmanjšanje odmerka zdravila PegIntron na 20 µg/m2/teden.
Both active substances have been available in the European Union (EU) as separate preparations for a number of years. 
Obe zdravilni učinkovini sta v Evropski uniji (EU) v obliki ločenih pripravkov na voljo že vrsto let.
The European Commission granted a marketing authorisation valid throughout the European Union for Omidria on 28 July 2015. 
Evropska komisija je dovoljenje za promet z zdravilom Omidria, veljavno po vsej Evropski uniji, izdala 28. julija 2015.
Other information about Omidria 
Druge informacije o zdravilu Omidria
What measures are being taken to ensure the safe and effective use of Omidria? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Omidria?
The full EPAR and risk management plan summary for Omidria can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Omidria sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Omidria. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Omidria.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Omidria are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Omidria večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). 
Ketorolak je nesteroidno protivnetno zdravilo (NSAID).
With regard to the safety of Omidria, the medicine was generally well tolerated. 
Z vidika varnosti zdravila Omidria so ga bolniki na splošno dobro prenašali.
What benefits of Omidria have been shown in studies? 
Kakšne koristi je zdravilo Omidria izkazalo v študijah?
Although the effect of Omidria on pain was modest, it was considered clinically important. 
Čeprav je bil učinek zdravila Omidria na bolečino zmeren, je bil klinično pomemben.
A risk management plan has been developed to ensure that Omidria is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Omidria je bil pripravljen načrt obvladovanja tveganj.
Phenylephrine is a ‘selective alpha-1 adrenergic receptor agonist', which attaches to and activates alpha-1 adrenergic receptors that are found on smooth muscle cells, causing these muscles to contract. 
Fenilefrin je „selektivni agonist alfa-1-adrenergičnih receptorjev“, ki se veže na alfa-1-adrenergične receptorje v celicah gladkih mišic in jih aktivira, kar povzroči skrčenje mišic.
What is Omidria and what is it used for? 
Kaj je zdravilo Omidria in za kaj se uporablja?
The most common side effects with Omidria (which may affect up to 1 in 10 people) are eye pain, anterior chamber inflammation (inflammation of the fluid-filled space inside the eye between the iris and the cornea), conjunctival hyperaemia (redness of the membrane that lies over the white part of the eye), photophobia (increased sensitivity of the eyes to light), corneal oedema (swelling of the transparent layer in front of the eye that covers the pupil and iris) and inflammation. 
Najpogostejši neželeni učinki zdravila Omidria (ki lahko prizadenejo največ 1 osebo od 10) bolečina v očesu, vnetje sprednjega očesnega prekata (vnetje s tekočino napolnjenega prostora v očesu med šarenico in roženico), hiperemija očesne veznice (pordelost membrane, ki prekriva beločnico), fotofobija (povečana občutljivost očesa za svetlobo), edem roženice (otekanje prozorne plasti sprednjega dela očesa, ki prekriva zenico in šarenico) in vnetje.
It works by blocking certain enzymes called cyclo-oxygenases, which produce prostaglandins, substances that are involved in pain and inflammation processes. 
Deluje tako, da zavira encime, imenovane ciklooksigenaze, ki proizvajajo prostaglandine, tj. snovi, ki sodelujejo pri bolečini in vnetnih procesih.
What are the risks associated with Omidria? 
Kakšna tveganja so povezana z zdravilom Omidria?
For more information about treatment with Omidria, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Omidria preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This is a type of surgery in which a new lens is implanted into the eye. 
To je vrsta kirurškega posega, pri katerem se v oko vsadi nova leča.
In both studies, the main measures of effectiveness were the change in diameter of the pupil by the end of the surgery, and how much eye pain patients felt soon after surgery, as indicated by the patient using a standard pain scale from 1 to 100. 
V obeh študijah sta bili glavni merili učinkovitosti sprememba premera zenice na koncu kirurškega posega in bolečina, ki so jo bolniki občutili takoj po kirurškem posegu in se je merila s standardno bolečinsko lestvico z rezultatom od 1 do 100.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Omidria, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For practical information about using Omidria, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Omidria naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The recommended dose is 4 ml of Omidria diluted in 500 ml of irrigation solution, to be used during the surgery to replace the lens. 
Priporočeni odmerek je 4 ml zdravila Omidria, razredčenega v 500 ml raztopine za izpiranje, ki se uporablja med kirurškim posegom za zamenjavo leče.
For the full list of all side effects reported with Omidria, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Omidria, glejte navodilo za uporabo.
It is not intended to provide practical advice on how to use Omidria. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The incidence of side effects with Omidria was similar to that reported in patients receiving placebo. 
Pogostnost neželenih učinkov zdravila Omidria je bila podobna pogostnosti, o kateri so poročali pri bolnikih, ki so prejemali placebo.
Both studies showed that the pupil remained dilated during surgery in patients given Omidria (+0.1 mm), while it contracted in those given placebo (-0.5 mm). 
V obeh študijah so pokazali, da je zenica med kirurškim posegom z zdravilom Omidria ostala razširjena (+0,1 mm), medtem ko se je pri placebu zožila (-0,5 mm).
It can only be obtained with a prescription and must be given by a qualified ophthalmological surgeon (eye surgery specialist) experienced in lens replacement. 
Izdaja zdravila je le na recept, uporabljati pa ga mora usposobljeni oftalmološki kirurg (specialist za očesne kirurške posege) z izkušnjami z zamenjavo leče.
Omidria must not be used in patients who have narrow-angle glaucoma, a serious condition of the eye in which the pressure inside the eye rises rapidly because fluid cannot drain out. 
Zdravilo Omidria se ne sme uporabljati pri bolnikih z glavkomom z zaprtim zakotjem, kar je resno očesno stanje, pri katerem se tlak v očesu hitro poviša zaradi nezmožnosti odtekanja tekočine.
This makes lens replacement surgery easier. 
To olajša kirurški poseg za zamenjavo leče.
Why is Omidria approved? 
Zakaj je bilo zdravilo Omidria odobreno?
Fewer than 1 in 10 of the patients given Omidria had a pupil diameter below 6 mm (which makes surgery more difficult), whereas about 4 patients in 10 experienced this after being given placebo. 
Manj kot 1 od 10 bolnikov, ki so prejeli zdravilo Omidria, je imelo premer zenice manjši od 6 mm (kar oteži kirurški poseg), medtem ko se je to zgodilo pri približno 4 od 10 bolnikov, ki so prejeli placebo.
Omidria phenylephrine / ketorolac 
Omidria fenilefrin/ketorolak
When applied to the eye, ketorolac reduces the production of prostaglandins in the eye and thereby reduces the pain and inflammation caused by eye surgery. 
Ko se ketorolak nanese v oko, zmanjša tvorbo prostaglandinov v očesu in tako zmanjša bolečino ter vnetje, ki ju povzroči očesni kirurški poseg.
The lens is the part of the eye that focuses light passing through the pupil and allows clear vision. 
Leča je del očesa, ki usmerja svetlobo, ki prehaja skozi zenico, in omogoča oster vid.
The ophthalmologist may also prescribe eye drops commonly used before and after the surgery to help prevent eye infections and pain. 
Okulist lahko predpiše tudi kapljice za oko, ki se navadno uporabljajo pred kirurškim posegom ter po njem in pomagajo preprečevati očesne okužbe ter bolečino.
Omidria is available as a concentrate that is made up into an irrigation solution (a solution used to rinse the inside of the eye during surgery). 
Zdravilo Omidria je na voljo v obliki koncentrata za pripravo raztopine za izpiranje (raztopina, ki se uporablja za izpiranje notranjosti očesa med kirurškim posegom).
Omidria has been shown to be effective at maintaining pupil dilation and preventing pupil contraction during lens replacement surgery, which should help to make such surgery easier and safer. 
Dokazali so, da je zdravilo Omidria učinkovito pri vzdrževanju razširjenosti zenice in preprečevanju zožitve zenice med kirurškim posegom za zamenjavo leče, kar omogoča preprostejši in varnejši kirurški poseg.
With respect to pain, patients treated with Omidria reported an average pain score of around 4, compared with around 9 for those given placebo. 
Bolniki, zdravljeni z zdravilom Omidria, so poročali o povprečnem rezultatu bolečine približno 4, pri placebu pa približno 9.
Omidria is a medicine used in adults during lens replacement surgery in the eye to keep the pupil dilated (widened) and prevent its contraction, and to reduce eye pain after surgery. 
Omidria je zdravilo, ki se uporablja pri odraslih med očesnim kirurškim posegom za zamenjavo leče, med katerim vzdržuje razširjenost zenice in preprečuje njeno skrčenje, ter za zmanjšanje bolečine v očesu po kirurškem posegu.
In addition, 7% (29 out of 403) of patients receiving Omidria experienced moderate-to-severe pain compared with 14% (57 out of 403) of patients given placebo, and 25% (104 out of 403) were painfree in the early period following surgery, compared with 17% (69 out of 403) of patients receiving placebo. 
Poleg tega je imelo 7 % (29 od 403) bolnikov, ki so prejeli zdravilo Omidria, zmerno do hudo bolečino v primerjavi s 14 % (57 od 403) bolnikov, ki so prejeli placebo.
Omidria has been investigated in two main studies involving a total of 821 patients undergoing lens replacement surgery, in which it was compared with placebo (a dummy treatment). 
Zdravilo Omidria so proučevali v dveh glavnih študijah, ki sta vključevali skupno 821 bolnikov, ki so bili naročeni na kirurški poseg za zamenjavo leče.
How is Omidria used? 
Kako se zdravilo Omidria uporablja?
How does Omidria work? 
Kako zdravilo Omidria deluje?
Omidria contains the active substances phenylephrine and ketorolac. 
Zdravilo Omidria vsebuje zdravilni učinkovini fenilefrin in ketorolak.
When applied to the eye, phenylephrine makes the muscle of the iris contract (tighten) and allows the pupil to widen. 
Ko se fenilefrin nanese v oko, se mišice šarenice skrčijo (napnejo), kar omogoči razširitev zenice.
These side effects are typical following lens replacement surgery, and most were mild to moderate in severity and resolved spontaneously. 
Večina jih je bila blagih do zmernih in so izginili spontano.
Therefore, AZILECT is not recommended for use under the age of 18. 
AZILECT ni priporočeno za mlajše od 18 let.
Smoking could decrease the amount of AZILECT in the blood. 
Kajenje lahko zmanjša količino zdravila AZILECT v krvi.
Its terminal half-life is 0.6-2 hours. 
2 mg. Njegov končni razpolovni čas je 0,6 do 2 uri.
The safety and efficacy of AZILECT in children and adolescents have not been established. 
Varnost in učinkovitost zdravila AZILECT pri otrocih in mladostnikih nista bili dokazani.
You should avoid taking AZILECT if you are pregnant, as the effects of AZILECT on pregnancy and the unborn child are not known. 
Izogibajte se jemanju zdravila AZILECT med nosečnostjo, ker učinki zdravila AZILECT na nosečnost in nerojenega otroka niso znani.
Do not stop taking AZILECT without first talking to your doctor. 
Ne prenehajte jemati zdravila AZILECT, ne da bi se prej pogovorili z zdravnikom.
AZILECT may be taken with or without food. 
Zdravilo AZILECT se lahko jemlje s hrano ali brez nje.
AZILECT helps to increase and sustain levels of dopamine in the brain. 
pomaga zvišati in vzdrževati raven dopamina v možganih.
What AZILECT is and what it is used for 
Kaj je zdravilo AZILECT in za kaj ga uporabljamo
Blisters: 3 years Bottles: 3 years 
Pretisni omoti: 3 leta Plastenka: 3 leta
What AZILECT is and what it is used for What you need to know before you take AZILECT How to take AZILECT 
Kaj je zdravilo AZILECT in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo AZILECT Kako jemati zdravilo AZILECT
Tablet 30 tablets 
tableta 30 tablet
Not known: frequency cannot be estimated from the available data - Elevated blood pressure - Excessive drowsiness - Sudden onset of sleep 
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) - povišan krvni tlak - prekomerna zaspanost - nenadni spanec
Take the AZILECT carton/ blister or bottle with you to show the doctor or pharmacist. 
S seboj vzemite škatlo/pretisni omot ali plastenko zdravila AZILECT, da jo boste lahko pokazali zdravniku ali farmacevtu.
This might be enhanced if you take other medicines to treat the symptoms of your Parkinson's disease, or if you take medicines which can make you feel drowsy, or if you drink alcohol while taking AZILECT. 
To se lahko okrepi, če med uporabo zdravila AZILECT jemljete druga zdravila za zdravljenje simptomov Parkinsonove bolezni, ali če jemljete zdravila, ki lahko povzročijo zaspanost, ali če pijete alkohol.
Symptoms reported following overdose of AZILECT included slightly euphoric mood (light form of mania), extremely high blood pressure and serotonin syndrome (see section 4). 
Simptomi, o katerih so poročali po prevelikem odmerjanju zdravila AZILECT, so vključevali rahlo evforično razpoloženje (lahka oblika manije), izredno visok krvni tlak in serotoninski sindrom (glejte poglavje 4).
Other medicines and AZILECT 
Druga zdravila in zdravilo AZILECT
The mean volume of distribution following a single intravenous dose of rasagiline is 243 l. Plasma protein binding following a single oral dose of 14C-labelled rasagiline is approximately 60 to 70%. 
Povprečni volumen porazdelitve, ki sledi enkratnemu intravenskemu odmerku razagilina, je 243 l. Plazemska proteinska vezava, ki sledi enojnemu odmerku s 14C-označenim razagilinom, je približno 60 do 70 %.
The metabolism of rasagiline proceeds through two main pathways: N-dealkylation and/or hydroxylation to yield: 1-aminoindan, 3-hydroxy-N-propargyl-1 aminoindan and 3-hydroxy-1-aminoindan. 
Presnova razagilina poteka preko dveh glavnih poti: N-dealkilacije in/ali hidroksilacije do presnovkov: 1-aminoindana, 3-hidroksi-Npropargil-1 aminoindana in 3-hidroksi-1-aminoindana.
Elderly No change in dose is required for elderly patients (see section 5.2). 
Starejši Za starejše bolnike ni potrebno spreminjanje odmerka (glejte poglavje 5.2).
The recommended dose of rasagiline is 1 mg (one tablet of AZILECT) once daily, to be taken with or without levodopa. 
Priporočeni odmerek razagilina je 1 mg (ena tableta zdravila AZILECT) enkrat dnevno, ki se jemlje z levodopo ali brez nje.
7 tablets 10 tablets 28 tablets 30 tablets 100 tablets 112 tablets 
7 tablet 10 tablet 28 tablet 30 tablet 100 tablet 112 tablet
What you need to know before you take AZILECT Do not take AZILECT 
Kaj morate vedeti, preden boste vzeli zdravilo AZILECT Ne jemljite zdravila AZILECT:
The use of AZILECT together with the antidepressants containing fluoxetine or fluvoxamine should be avoided. 
Potrebno se je izogibati uporabi zdravila AZILECT skupaj z antidepresivi, ki vsebujejo fluoksetin ali fluvoksamin.
The tablets are available in blister packs of 7, 10, 28, 30, 100 and 112 tablets or in a bottle containing 30 tablets. 
Tablete so na voljo v pretisnih omotih v škatli po 7, 10, 28, 30, 100 in 112 tablet ali v plastenki s 30 tabletami.
AZILECT contains the active substance rasagiline and it is used for the treatment of Parkinson's disease in adults. 
Zdravilo AZILECT vsebuje učinkovino razagilin in se uporablja pri zdravljenju Parkinsonove bolezni pri odraslih.
If you forget to take AZILECT 
Če ste pozabili vzeti zdravilo AZILECT
The difference between the mean change from baseline to week 26/termination (LOCF, Last Observation Carried Forward) was statistically significant (UPDRS, parts I-III: for rasagiline 1 mg compared to placebo -4.2, 95% CI [-5.7, -2.7]; p<0.0001; for rasagiline 2 mg compared to placebo -3.6, 95% CI [-5.0, -2.1]; p<0.0001, UPDRS Motor, part II: for rasagiline 1 mg compared to placebo -2.7, 95% CI [-3.87, -1.55], p<0.0001; for rasagiline 2 mg compared to placebo -1.68, 95% CI [-2.85, -0.51], p=0.0050). 
Razlika med povprečno spremembo od izhodišča do 26. tedna/zaključka (zadnje opazovanje preneseno vnaprej; Last Observation Carried Forward - LOCF) je bila statistično pomembna (UPDRS, deli I-III: za razagilin 1 mg v primerjavi s placebom -4,2, 95 % IZ [-5,7; -2,7]; p < 0,0001; za razagilin 2 mg v primerjavi s placebom -3,6, 95 % IZ [-5,0; -2,1]; p < 0.0001; UPDRS motorični, del II: za razagilin 1 mg v primerjavi s placebom -2,7, 95 % IZ [-3,87; -1,55]; p < 0,0001; za razagilin 2 mg v primerjavi s placebom -1,68, 95 % IZ [-2,85; -0,51]; p = 0,0050).
Symptoms reported following overdose of rasagiline in doses ranging from 3 mg to 100 mg included hypomania, hypertensive crisis and serotonin syndrome. 
Simptomi Simptomi, ki so jih navajali pri prevelikem odmerku razagilina pri odmerkih od 3 mg do 100 mg, so vključevali hipomanijo, hipertenzivno krizo in serotoninski sindrom.
There is no relevant use of AZILECT in the paediatric population in the indication Parkinson's disease. 
Zdravilo AZILECT ni namenjeno za uporabo pri pediatrični populaciji za indikacijo Parkinsonove bolezni.